Unwarranted pessimism has driven the shares down.
I like living, breathing examples of growth stocks going right.
They should improve shareholder value in coming months.
Here's what we'd need to see before trying a reentry.
What that means for investors and policymakers alike.
This biotech comes with high hopes and question marks.
Regeron's technicals -- and the current pullback -- all add up to a buy.
This rollup name is on the stock-market equivalent of steroids.
Any remedies for managed-care companies and Medicaid HMOs?
Kindred Biosciences is a unique player in an underserved market.


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.